| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LOS ANGELES—Looking to tap into the world's biggest biotech center, biomedical development company Genesis Bioventures, Inc. (GBI) announced it has opened its new corporate headquarters in Los Angeles, just down the highway from its former location in Vancouver. The move is part of a restructuring and reorganization that the company announced in 2005.
 
"The office location we selected is in the heart of one of California's top finance, business, research, and technology centers, and gives us immediate high-level access to key business, commercial and science resources that we intend to fully utilize to grow our company," said Douglas Lane, GBI CEO and chairman.
 
With the restructuring completed, the company is looking to enter a significant growth phase and is opening its doors to potential partners that will facilitate the achievement of its commercial objectives.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue